http://www.mmm-online.com/comarketing/topic/12011/ Articles tagged with Co-Marketing from Medical Marketing and Media MMM mmmsubs@haymarketmedia.com no Lundbeck and Otsuka deepen their Abilify co-promotion partnership; study finds FDA clinical trial rule isn't sticking; another study confirms that employees are paying more for health insurance as employers pay less; Merck appoints new R&D chief http://www.mmm-online.com/business-briefs-lundbeck-fda-tower-watson-and-national-business-group-study-merck/article/283382/ Thu, 07 Mar 2013 17:01:19 GMT Lundbeck and Otsuka deepen their Abilify co-promotion partnership; study finds FDA clinical trial rule isn't sticking; another study confirms that employees are paying more for health insurance as employers pay less; Merck appoints new R&D chief MMM GlaxoSmithKline returned marketing rights on epilepsy drug Horizant to XenoPort effective April 30, 2013. http://www.mmm-online.com/company-news-gsk-salix/article/267584/ Thu, 08 Nov 2012 21:30:00 GMT GlaxoSmithKline returned marketing rights on epilepsy drug Horizant to XenoPort effective April 30, 2013. MMM Auxilium inked a co-promote deal with GSK on its Testim 1% testosterone gel for the US. http://www.mmm-online.com/company-news-auxilium-and-gsk-jjs-janssen/article/242322/ Tue, 22 May 2012 19:13:37 GMT Auxilium inked a co-promote deal with GSK on its Testim 1% testosterone gel for the US. MMM WebMD the Magazine is now part of the iPad app world. http://www.mmm-online.com/company-news-webmd-wiley-blackwell-and-eli-lillyboehringer-ingelheim/article/230974/ Wed, 07 Mar 2012 15:30:07 GMT WebMD the Magazine is now part of the iPad app world. MMM Amylin said it will hire 365 sales reps to make up for Eli Lilly's departure from commercial activities, once the firm takes full control of the exenatide diabetes franchise in the US this month. http://www.mmm-online.com/amylin-parting-ways-with-lilly-plans-for-extra-sales-reps/article/216291/ Tue, 08 Nov 2011 17:45:28 GMT Amylin said it will hire 365 sales reps to make up for Eli Lilly's departure from commercial activities, once the firm takes full control of the exenatide diabetes franchise in the US this month. MMM Vertex has succeeded in bringing one heck of a new drug to market in Incivek (in-SEE-veck, or telaprevir), a hepatitis C drug 15 years in the making which promises to cut treatment time in half. Selling the drug against the combined might of Roche and Merck could be nearly as tricky. http://www.mmm-online.com/vertex-versus-goliaths-in-hcv-drug-duel/article/203611/ Tue, 24 May 2011 03:43:38 GMT Vertex has succeeded in bringing one heck of a new drug to market in Incivek (in-SEE-veck, or telaprevir), a hepatitis C drug 15 years in the making which promises to cut treatment time in half. Selling the drug against the combined might of Roche and Merck could be nearly as tricky. MMM Roche will help promote Merck's newly approved hepatitis C drug Victrelis (boceprevir) under a strategic partnership that may help bolster the firms' chances in an upcoming market share battle. The agreement stunned Wall Street, since Merck and Roche already sell rival versions of a standard hepatitis C treatment. http://www.mmm-online.com/roche-to-co-promote-mercks-victrelis-in-us/article/203083/ Tue, 17 May 2011 20:01:50 GMT Roche will help promote Merck's newly approved hepatitis C drug Victrelis (boceprevir) under a strategic partnership that may help bolster the firms' chances in an upcoming market share battle. The agreement stunned Wall Street, since Merck and Roche already sell rival versions of a standard hepatitis C treatment. MMM Lilly/Boehringer Ingelheim's third-to-market DPP-4 inhibitor Tradjenta, approved earlier this week for the treatment of type 2 diabetes, faces an uphill battle for market share against Merck's entrenched market leader Januvia and BMS/AstraZeneca's Onglyza. http://www.mmm-online.com/for-tradjenta-a-tough-climb-and-for-lilly-a-vital-one/article/202204/ Thu, 05 May 2011 19:11:07 GMT Lilly/Boehringer Ingelheim's third-to-market DPP-4 inhibitor Tradjenta, approved earlier this week for the treatment of type 2 diabetes, faces an uphill battle for market share against Merck's entrenched market leader Januvia and BMS/AstraZeneca's Onglyza. MMM Teva is partnering with Procter & Gamble in an OTC drug marketing joint venture that will boast annual sales of more than $1 billion -- and which could ultimately be worth four times that, the companies say. http://www.mmm-online.com/teva-pg-partner-to-form-global-otc-behemoth/article/199119/ Thu, 24 Mar 2011 20:29:08 GMT Teva is partnering with Procter & Gamble in an OTC drug marketing joint venture that will boast annual sales of more than $1 billion -- and which could ultimately be worth four times that, the companies say. MMM